title: Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine.
abstract: We previously developed a dengue tetravalent DNA vaccine that can induce neutralizing antibodies against four dengue viruses in mice. Here, we demonstrated that immunogenicity of our tetravalent vaccine is synergistically increased in mice by co-immunization with dengue type 2 virus (DENV2) subviral extracellular particles (D2EPs) or inactivated Japanese encephalitis vaccine (JEVAX). A single immunization with a mixture of 100 microg of the tetravalent vaccine and 150 ng of D2EPs or a 1/10 dose of JEVAX induced moderate levels of neutralizing antibodies in a 90% plaque reduction assay. Immunized mice were protected from "artificial" viremia created by intravenous injection with DENV2.
authors.affiliation: Department of Health Sciences, Kobe University School of Medicine, 7-10-2 Tomogaoka, Suma-ku, Kobe 654-0142, Japan.
authors.forename: Jun-Ichi
authors.initials: J
authors.lastname: Imoto
authors.forename: Eiji
authors.initials: E
authors.lastname: Konishi
mesh_terms: D000818:Animals; D002522:Chlorocebus aethiops; D003715:Dengue / Q000276:immunology / Q000517:prevention & control; D053059:Dengue Vaccines / Q000276:immunology* / Q000627:therapeutic use; D022321:Japanese Encephalitis Vaccines / Q000276:immunology* / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D017778:Vaccines, Combined / Q000276:immunology / Q000627:therapeutic use; D019444:Vaccines, DNA / Q000276:immunology* / Q000627:therapeutic use; D015164:Vaccines, Inactivated / Q000276:immunology / Q000627:therapeutic use; D014709:Vero Cells; D014766:Viremia / Q000276:immunology / Q000517:prevention & control / Q000821:virology
chemical_list: D053059:Dengue Vaccines; D022321:Japanese Encephalitis Vaccines; D017778:Vaccines, Combined; D019444:Vaccines, DNA; D015164:Vaccines, Inactivated